Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2Sezary Syndrome 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Hodgkin Disease 1Hematologic Neoplasms 1Cytomegalovirus Infections 1

Interventions

fludarabine phosphate 19Whole-Body Irradiation 15Peripheral Blood Stem Cell Transplantation 15Mycophenolic Acid 15Tacrolimus 12Cyclosporine 11Cyclophosphamide 11Antilymphocyte Serum 11Busulfan 10Rituximab 7Methotrexate 7Etoposide 6Melphalan 5Flow Cytometry 5Radiotherapy 4Panobinostat 4Lenalidomide 4Filgrastim 4Everolimus 4Dexamethasone 4Calcium Dobesilate 4thymoglobulin 3romidepsin 3pembrolizumab 3mogamulizumab 3fludarabine 3Therapeutics 3Sirolimus 3In Situ Hybridization, Fluorescence 3Immunohistochemistry 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Sezary Syndrome × letermovir × Clear all
NCT04312841 2025-02-28

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
6 enrolled 11 charts
DermatologicLymphoidOther hematologic neoplasm

Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡